<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="31">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05160740</url>
  </required_header>
  <id_info>
    <org_study_id>2021-KY-090-01</org_study_id>
    <nct_id>NCT05160740</nct_id>
  </id_info>
  <brief_title>Indocyanine Green Molecular Fluorescence Imaging Technique Using in Diagnosis and Treatment of Primary Liver Cancer</brief_title>
  <acronym>ICGMFITinPLC</acronym>
  <official_title>Multicenter Randomized Controlled Clinical Trial of Indocyanine Green Molecular Fluorescence Imaging in the Diagnosis and Treatment of Primary Liver Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhujiang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhujiang Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The of this study is to explore the clinical outcomes of indocyanine green molecular&#xD;
      fluorescence imaging in local resection of primary hepatocellular carcinoma (CNLC â… a stage).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Indocyanine green molecular imaging technique is often used in the surgical treatment of&#xD;
      primary liver cancer. Its application in hepatectomy of primary liver cancer is currently in&#xD;
      the stage of case accumulation and clinical research. No prospective study has been conducted&#xD;
      to determine the clinical efficacy of indocyanine green molecular imaging for local&#xD;
      hepatectomy of primary liver cancer. On the basis of more than 1000 liver resection&#xD;
      procedures, we want to apply indocyanine green molecular imaging technology, a cheap, simple&#xD;
      and radiation-free method, to guide surgical resection. The purpose is to assist surgical&#xD;
      procedures and improve patients' tumor-free survival.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 23, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>3-year disease free survival rate</measure>
    <time_frame>36 months</time_frame>
    <description>No tumor recurrence within 3 years after surgery divided by total number of patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Positive margin rate</measure>
    <time_frame>14 days</time_frame>
    <description>Compare positive margin rate in both groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Negative margin rate</measure>
    <time_frame>14 days</time_frame>
    <description>Compare negative margin rate in both groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of the shortest cutting edge</measure>
    <time_frame>14 days</time_frame>
    <description>The shortest distance between tumor and resection margin was compared between the two groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Operation time</measure>
    <time_frame>1 day</time_frame>
    <description>Compare operation time in both groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraoperative blood loss</measure>
    <time_frame>1 day</time_frame>
    <description>Compare intraoperative blood loss in both groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraoperative blood transfusion volume</measure>
    <time_frame>1 day</time_frame>
    <description>Compare intraoperative blood transfusion volume in both groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of small lesions of HCC</measure>
    <time_frame>14 days</time_frame>
    <description>Small lesions detected by ICG fluorescence and confirmed by pathology in the intervention group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Residual tumor at the margin of liver cross-section</measure>
    <time_frame>14 days</time_frame>
    <description>The number of residual tumors confirmed by ICG fluorescence detection at the liver margin of the intervention group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraoperative biliary fistula detection rate</measure>
    <time_frame>1 day</time_frame>
    <description>The number of cases of successful intraoperative detection of biliary fistula by fluorescence in the intervention group divided by the total number of cases in the intervention group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extrahepatic metastases of primary hepatocellular carcinoma</measure>
    <time_frame>14 days</time_frame>
    <description>The number of extrahepatic metastases of primary liver cancer detected by ICG and confirmed by pathology in the intervention group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative hospital stay</measure>
    <time_frame>30 days</time_frame>
    <description>Compare Postoperative hospital stay in both groups. Eg: Postoperative hospital stay is the number of days from the day of surgery to the day of discharge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative liver function index 1</measure>
    <time_frame>5 days</time_frame>
    <description>Compare the levels of Alanine aminotransferase on postoperative days 1, 3, and 5 in both groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative liver function index 2</measure>
    <time_frame>5 days</time_frame>
    <description>Compare the levels of Aspartate aminotransferase on postoperative days 1, 3, and 5 in both groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative liver function index 3</measure>
    <time_frame>5 days</time_frame>
    <description>Compare the levels of serum albumin on postoperative days 1, 3, and 5 in both groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative liver function index 4</measure>
    <time_frame>5 days</time_frame>
    <description>Compare the levels of total bilirubin on postoperative days 1, 3, and 5 in both groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative hemoglobin</measure>
    <time_frame>5 days</time_frame>
    <description>Compare hemoglobin on postoperative days 1, 3, and 5 in both groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative platelets</measure>
    <time_frame>5 days</time_frame>
    <description>Compare platelets on postoperative days 1, 3, and 5 in both groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prothrombin time</measure>
    <time_frame>5 days</time_frame>
    <description>Compare prothrombin time on postoperative days 1, 3, and 5 in both groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality rates</measure>
    <time_frame>3 months</time_frame>
    <description>Perioperative death was defined as death occurring within 90 days after surgery</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">348</enrollment>
  <condition>Liver Cancer</condition>
  <arm_group>
    <arm_group_label>ICG molecular fluorescence imaging guided surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ICG molecular fluorescence imaging will be used in local hepatectomy of primary liver cancer in this group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No ICG molecular fluorescence imaging guided surgery</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>ICG molecular fluorescence imaging will not be used in local hepatectomy of primary liver cancer in this group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indocyanine green for injection</intervention_name>
    <description>Surgical guidance based on ICG molecular fluorescence image</description>
    <arm_group_label>ICG molecular fluorescence imaging guided surgery</arm_group_label>
    <arm_group_label>No ICG molecular fluorescence imaging guided surgery</arm_group_label>
    <other_name>ICG</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  First clinical diagnosis of primary liver cancer (China liver cancer staging, CNLC Ia&#xD;
             stage);&#xD;
&#xD;
          -  Child-Pugh grading standard of liver function was GRADE A or B;&#xD;
&#xD;
          -  18-66 years old;&#xD;
&#xD;
          -  Complete clinical case data;&#xD;
&#xD;
          -  limited surgical methods (local resection);&#xD;
&#xD;
          -  Voluntarily participate in the study and sign the informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  There are basic diseases that cannot tolerate surgery (such as severe cardiopulmonary&#xD;
             cerebral renal insufficiency);&#xD;
&#xD;
          -  Tumor thrombus or distant metastasis was found in main portal vein and primary branch,&#xD;
             main hepatic vein and branch, main hepatic vein and inferior vena cava by preoperative&#xD;
             imaging examination;&#xD;
&#xD;
          -  planned pregnancy, unplanned pregnancy and pregnancy;&#xD;
&#xD;
          -  Preoperative child-Pugh grading standard of liver function was Grade C.&#xD;
&#xD;
          -  Disease researchers that the investigator considers inappropriate to participate in&#xD;
             this clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>66 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chihua Fang, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Zhujiang Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chihua Fang, MD</last_name>
    <phone>13609700805</phone>
    <email>fangchihua@smu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiaojun Zeng</last_name>
    <phone>15626104890</phone>
    <email>zengxiaojun95@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Zhujiang Hospital of Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510282</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chihua Fang, M.D</last_name>
      <phone>(+86)2062782568</phone>
      <email>fangch_dr@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Xiaojun Zeng</last_name>
      <phone>(+86)2062782568</phone>
      <email>zengxiaojun95@126.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>November 9, 2021</study_first_submitted>
  <study_first_submitted_qc>December 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2021</study_first_posted>
  <last_update_submitted>December 2, 2021</last_update_submitted>
  <last_update_submitted_qc>December 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zhujiang Hospital</investigator_affiliation>
    <investigator_full_name>Chihua Fang,MD</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>indocyanine green</keyword>
  <keyword>local resection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

